Company news

PDS Biotechnology Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

February 20, 2025

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

February 4, 2025

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

December 2, 2024

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

November 13, 2024

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8: 30 a.m. Eastern Time

November 5, 2024

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

October 21, 2024

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

October 1, 2024

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

September 15, 2024

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

September 8, 2024

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

August 12, 2024

PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting

August 7, 2024

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

August 6, 2024

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024

August 4, 2024

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

July 31, 2024

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

July 30, 2024

PDS Biotech to Participate at BTIG Virtual Biotechnology Conference

July 28, 2024

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

June 11, 2024

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

May 14, 2024

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

May 8, 2024

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

May 8, 2024

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

May 6, 2024

PDS Biotechnology Announces Details of Virtual KOL Event

May 2, 2024

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

May 1, 2024

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

April 22, 2024

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

March 26, 2024

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

March 19, 2024

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

March 12, 2024

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

January 21, 2024

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

January 15, 2024

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

November 27, 2023

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

November 8, 2023

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

November 6, 2023

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

October 22, 2023

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

October 10, 2023

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

October 2, 2023

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

October 1, 2023

PDS Biotech to Present at the LD Micro Main Event XVI

September 25, 2023

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

September 24, 2023

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

September 19, 2023

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

September 19, 2023

PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023

September 12, 2023

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

September 5, 2023

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting

August 15, 2023

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

August 13, 2023

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

August 13, 2023

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

August 6, 2023

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

August 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.